Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.078 +0.208 (+5.36%)

Streaming Delayed Price Updated: 1:52 PM EDT, Jul 30, 2026 Add to My Watchlist

Price and Volume

Volume	109,232
Open	3.940
Bid (Size)	4.070 (100)
Ask (Size)	4.090 (200)
Prev. Close	3.870
Today's Range	3.920 - 4.105
52wk Range	3.710 - 7.750
Shares Outstanding	9,947,915
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

June 18, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

June 15, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Performance

YTD	-27.8%	-27.8%
1 Month	-32.8%	-32.8%
3 Month	+0.2%	+0.2%
6 Month	-11.4%	-11.4%
1 Year	-36.3%	-36.3%

More News

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

June 08, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit

May 27, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 12, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

May 12, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

April 09, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

April 02, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

March 18, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

March 16, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

February 10, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces $11.1 Million Private Placement

January 30, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

January 20, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

January 08, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

January 05, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

December 23, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

December 09, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

November 25, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

November 12, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

November 04, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

October 27, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Get insights into the top gainers and losers of Friday's pre-market session. ↗

October 24, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 24, 2025

Via Benzinga

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

October 24, 2025

From Coya Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 23, 2025

Via Benzinga

Frequently Asked Questions

Is Coya Therapeutics, Inc. - Common Stock publicly traded?

Yes, Coya Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Coya Therapeutics, Inc. - Common Stock trade on?

Coya Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Coya Therapeutics, Inc. - Common Stock?

The ticker symbol for Coya Therapeutics, Inc. - Common Stock is COYA on the Nasdaq Stock Market

What is the current price of Coya Therapeutics, Inc. - Common Stock?

The current price of Coya Therapeutics, Inc. - Common Stock is 4.078

When was Coya Therapeutics, Inc. - Common Stock last traded?

The last trade of Coya Therapeutics, Inc. - Common Stock was at 07/30/26 01:52 PM ET

What is the market capitalization of Coya Therapeutics, Inc. - Common Stock?

The market capitalization of Coya Therapeutics, Inc. - Common Stock is 40.56M

How many shares of Coya Therapeutics, Inc. - Common Stock are outstanding?

Coya Therapeutics, Inc. - Common Stock has 41M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.